Skip To Main Content
Michael Erman on Muck Rack

Michael Erman

Verified
United States
As seen in: Reuters, Folha de S.Paulo, G1 Globo, MSN, MSN Australia, MSN Brasil, MSN Canada, MSN India, MSN Ireland, MSN Money Canada, MSN Singapore and
I write for Reuters. My articles can be found here: www.reuters.com/journalists/michael-erman
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Michael Erman’s profile

Articles by Michael Erman

J&J posts weak medical device sales, shares fall

|
By Michael Erman Verified, Sriparna Roy Verified
| Reuters Verified
People gather next to a logo of Johnson & Johnson at the company’s booth at the 8th China International Import Expo (CIIE) in Shanghai, China, November 6, 2025.REUTERS/Maxim Shemetov/File Photo Purchase Licensing Rights, opens new tab Company aims for ortho business spinoff by mid 2027 Tremfya sales jump 68% J&J raises full-year forecast CFO says Middle East conflict, European austerity and China pricing pressures weighed on device sales Oct 13 (Reuters) - Johnson & Johnson (JNJ.N), opens new...
Open in Who Shared Issue with article?

J&J beats earnings estimates; Middle East conflict weighs on medical device sales

|
By Michael Erman Verified
| The Globe and Mail Verified
Open in Who Shared View Duplicates (5) Issue with article?

J&J beats earnings estimates; Middle East conflict weighs on medical device sales

|
By Michael Erman Verified
| MSN Verified
By Michael Erman Oct 13 (Reuters) - Johnson & Johnson reported a slightly higher-than-expected profit on Tuesday, driven by strong sales of immune disease treatment Tremfya, but geopolitical issues including the Middle East conflict were a drag on its medical devices business. The company posted third-quarter revenue of $25.4 billion, above analysts' average estimate of $25.28 billion, according to LSEG data. Adjusted earnings of $2.59 per share also topped Wall Street expectations of $2.54.
Open in Who Shared View Duplicates (126) Issue with article?

J&J posts weak medical device sales, shares fall

|
By Michael Erman Verified, Sriparna Roy Verified
| MarketScreener
Oct 13 (Reuters) - Johnson & Johnson reported sales in its medical devices business on Tuesday that fell short of Wall Street expectations, citing geopolitical issues including the Middle East conflict, and its shares fell more than 6%. The results marked the second successive quarter that its MedTech unit missed analysts' estimates.
Open in Who Shared View Duplicates (4) Issue with article?

J&J beats earnings estimates, eyes hip-knee unit spinoff by mid-2027

|
By Michael Erman Verified
| Tacoma News Tribune Verified
Oct 13 (Reuters) - Johnson & Johnson reported a slightly higher-than-expected profit on Tuesday driven by strong sales of immune disease treatment Tremfya, and said it plans to spin off its hips and knees business next year. The company had late last year said it intended to separate its orthopedics unit, DePuy Synthes, into a standalone company, marking its second major spinoff as it sharpens focus on higher-growth healthcare segments.
Open in Who Shared Issue with article?

J&J beats earnings estimates, eyes hip-knee unit spinoff by mid-2027

|
By Michael Erman Verified
| Mahoning Matters Verified
Oct 13 (Reuters) - Johnson & Johnson reported a slightly higher-than-expected profit on Tuesday driven by strong sales of immune disease treatment Tremfya, and said it plans to spin off its hips and knees business next year. The company had late last year said it intended to separate its orthopedics unit, DePuy Synthes, into a standalone company, marking its second major spinoff as it sharpens focus on higher-growth healthcare segments.
Open in Who Shared Issue with article?

J&J beats earnings estimates, eyes hip-knee unit spinoff by mid-2027

|
By Michael Erman Verified
| Bradenton Herald Verified
Oct 13 (Reuters) - Johnson & Johnson reported a slightly higher-than-expected profit on Tuesday driven by strong sales of immune disease treatment Tremfya, and said it plans to spin off its hips and knees business next year. The company had late last year said it intended to separate its orthopedics unit, DePuy Synthes, into a standalone company, marking its second major spinoff as it sharpens focus on higher-growth healthcare segments.
Open in Who Shared Issue with article?

J&J posts weak medical device sales, shares fall

|
By Michael Erman Verified, Sriparna Roy Verified
| The Sacramento Bee Verified
Oct 13 (Reuters) - Johnson & Johnson reported sales in its medical devices business on Tuesday that fell short of Wall Street expectations, citing geopolitical issues including the Middle East conflict, and its shares fell more than 6%. The results marked the second successive quarter that its MedTech unit missed analysts' estimates.
Open in Who Shared Issue with article?

J&J beats earnings estimates, eyes hip-knee unit spinoff by mid-2027

|
By Michael Erman Verified
| The Sun News Verified
Oct 13 (Reuters) - Johnson & Johnson reported a slightly higher-than-expected profit on Tuesday driven by strong sales of immune disease treatment Tremfya, and said it plans to spin off its hips and knees business next year. The company had late last year said it intended to separate its orthopedics unit, DePuy Synthes, into a standalone company, marking its second major spinoff as it sharpens focus on higher-growth healthcare segments.
Open in Who Shared Issue with article?

J&J beats earnings estimates, eyes hip-knee unit spinoff by mid-2027

|
By Michael Erman Verified
| The Telegraph (Macon) Verified
Oct 13 (Reuters) - Johnson & Johnson reported a slightly higher-than-expected profit on Tuesday driven by strong sales of immune disease treatment Tremfya, and said it plans to spin off its hips and knees business next year. The company had late last year said it intended to separate its orthopedics unit, DePuy Synthes, into a standalone company, marking its second major spinoff as it sharpens focus on higher-growth healthcare segments.
Open in Who Shared Issue with article?
Show More